Omeros Stock Lifted By Positive Phase 2 Clinical Data
October 17, 2016 at 08:58 AM EDT
Omeros Corporation (NASDAQ: OMER) reported positive initial results for its Phase 2 trial of OMS721, a complement inhibitor for renal ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.